AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25775441 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 135
Study 23452680 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC)
Number of subjects: 39
Study 23452680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 20071099 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention deficit symptoms
Number of subjects: 75
Study 20071099 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperactivity symptoms
Number of subjects: 75
Study 20071099 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline attention deficit symptoms
Number of subjects: 75
Study 20071099 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hyperactivity symptoms
Number of subjects: 75
Study 18261100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional 5-fluorouracil, lidocaine, and epinephrine (5-FU+LE) - 4 mL of 50 mg/mL 5-fluorouracil and 1 mL of a mixture of 20 mg/mL [2%] lidocaine and 0.0125 mg/mL epinephrine, administered up to four times at weekly intervals.
Number of subjects: 34
Study 18261100 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intralesional normal saline)
Number of subjects: 34
Study 16813531 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (5 mg/day, orally)
Number of subjects: 0
Study 16813531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14597516 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aminocaproic acid (Caprogel)
Number of subjects: 51
Study 14597516 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 51
Study 10892526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM) intervention for 10 weeks
Number of subjects: 59
Study 10892526 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group for 10 weeks
Number of subjects: 59
Study 8635109 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + RT (Cisplatin 100mg/m2 on day 1, 5-fluorouracil 1000 mg/m2 from day 1 to 5, followed by RT)
Number of subjects: 94
Study 8635109 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + RT
Number of subjects: 94
Study 8635109 — intervention group
Group type: COMPARATOR
Intervention: RT (64.8 Gy in 1.8 Gy fractions)
Number of subjects: 94
Study 8635109 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 94
Study 1429349 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal audiotapes from a manufacturer
Number of subjects: 3
Study 1429349 — intervention group
Group type: COMPARATOR
Intervention: Placebo tapes
Number of subjects: 3
Study 1429349 — intervention group
Group type: COMPARATOR
Intervention: No tapes
Number of subjects: 3
Study 3914174 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha‐2C monotherapy
Number of subjects: 42
Study 3914174 — intervention group
Group type: COMPARATOR
Intervention: VMCP‐polychemotherapy
Number of subjects: 42
Study 31838879 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-mediated cognitive behavioral exercise and dietary intervention (EX+D)
Number of subjects: 32
Study 31838879 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SC) treatment
Number of subjects: 32
Study 30024539 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 27
Study 30024539 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal skin)
Number of subjects: 27
Study 26513278 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotics (short‐chain galacto‐oligosaccharids/long‐chain fructo‐oligosacarids)
Number of subjects: 50
Study 26513278 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 50
Study 25351119 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional nursing and peer education
Number of subjects: 240
Study 25351119 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing
Number of subjects: 240
Study 22770649 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg/day for 1 week
Number of subjects: 60
Study 22770649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20413968 — intervention group
Group type: EXPERIMENTAL
Intervention: Flour fortification with iron
Number of subjects: 200
Study 20413968 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-fortified flour)
Number of subjects: 200
Study 17493108 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine lozenges
Number of subjects: 1030
Study 17493108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1030
Study 16221950 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee sting therapy (live bees, up to 20, administered three times per week for 24 weeks)
Number of subjects: 26
Study 16221950 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee sting therapy
Number of subjects: 26
Study 16221950 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 26
Study 12030735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous steroids and aerosol bronchodilators (40 mg methylprednisolone IV, decreasing to 20 mg after 10 days, then 4 mg x 4 days; 10 mg salbutamol and 1 mg ipratropiumbromide aerosol therapy)
Number of subjects: 37
Study 12030735 — intervention group
Group type: COMPARATOR
Intervention: Oral steroids and MDI bronchodilators (32 mg methylprednisolone orally for 1 week, then 24 mg x day(‐1) for 4 days, decreasing to 4 mg x week(‐1); 1.6 mg fenoterol and 640 microg ipratropiumbromide MDI with a spacer)
Number of subjects: 37
Study 9888878 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 23
Study 9888878 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study 7741534 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous enterostatin (D3800) 4 mg
Number of subjects: 18
Study 7741534 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous enterostatin (D3800) 16 mg
Number of subjects: 18
Study 7741534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1675527 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide with gum rosin vehicle
Number of subjects: 0
Study 1675527 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide with hydrocolloid vehicle
Number of subjects: 0
Study 7040229 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine
Number of subjects: 2529
Study 7040229 — intervention group
Group type: COMPARATOR
Intervention: No reserpine
Number of subjects: 2529
Study 31860466 — intervention group
Group type: EXPERIMENTAL
Intervention: Protection-motivation theory constructs
Number of subjects: 380
Study 29536205 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of dexamethasone orally 1 hour before the procedure
Number of subjects: 50
Study 29536205 — intervention group
Group type: COMPARATOR
Intervention: 4 mg dexamethasone orally 1 hour before and 24 hours after the procedure
Number of subjects: 50
Study 27641781 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 52
Study 27641781 — intervention group
Group type: COMPARATOR
Intervention: Self-Monitoring of Blood Glucose (SMBG)
Number of subjects: 52
Study 24699466 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational vaccine formulations (10 or 30μg each of dPly and PhtD, alone or in combination with PHiD-CV)
Number of subjects: 257
Study 24699466 — intervention group
Group type: COMPARATOR
Intervention: PHiD-CV (licensed vaccine)
Number of subjects: 257
Study 24699466 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg dPly/PhtD with PHiD-CV-conjugates
Number of subjects: 257
Study 24699466 — intervention group
Group type: EXPERIMENTAL
Intervention: All pneumococcal protein-containing formulations
Number of subjects: 257
Study 22432716 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofunctional treatment (NFT)
Number of subjects: 23
Study 22432716 — intervention group
Group type: COMPARATOR
Intervention: Control group (after crossover)
Number of subjects: 23
Study 19280178 — intervention group
Group type: EXPERIMENTAL
Intervention: Early active range of motion rehabilitation using a bicycle ergometer equipped with an adjustable pedal arm, 6 sessions over 2 weeks post-operatively under supervision
Number of subjects: 31
Study 19280178 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study 17225879 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 50
Study 17225879 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 50
Study 17225879 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 15204674 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine maintenance treatment
Number of subjects: 139
Study 15204674 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance treatment
Number of subjects: 139
Study 12426274 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed administration of the Chronic Respiratory Questionnaire (CRQ)
Number of subjects: 85
Study 12426274 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed administration of the St. George's Respiratory Questionnaire (SGRQ)
Number of subjects: 85
Study 12426274 — intervention group
Group type: COMPARATOR
Intervention: Blind administration of the CRQ
Number of subjects: 85
Study 12426274 — intervention group
Group type: COMPARATOR
Intervention: Blind administration of the SGRQ
Number of subjects: 85
Study 10458359 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy
Number of subjects: 278
Study 10458359 — intervention group
Group type: COMPARATOR
Intervention: Control (radical prostatectomy alone)
Number of subjects: 278
Study 10458359 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic intraepithelial neoplasia
Number of subjects: 278
Study 10458359 — intervention group
Group type: COMPARATOR
Intervention: No prostatic intraepithelial neoplasia
Number of subjects: 278
Study 7614504 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril
Number of subjects: 257
Study 7614504 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 257
Study 2699071 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive irradiation
Number of subjects: 0
Study 2699071 — intervention group
Group type: COMPARATOR
Intervention: Cystectomy
Number of subjects: 0
Study 2699071 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 795610 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg naproxen twice daily
Number of subjects: 191
Study 795610 — intervention group
Group type: COMPARATOR
Intervention: 50 mg indomethacin twice daily
Number of subjects: 191
Study 30882524 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural boluses (6-mL every 45 minutes of 0.1% ropivacaine with 2 µg/mL fentanyl)
Number of subjects: 120
Study 30882524 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion (8 mL/h of 0.1% ropivacaine with 2 µg/mL fentanyl)
Number of subjects: 120
Study 29947142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive games group (experimental group) - card and board games training executive functions, 30-min training session twice a week for six weeks.
Number of subjects: 118
Study 29947142 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (regular school lessons).
Number of subjects: 118
Study 28513426 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (pregabalin 150-mg capsule)
Number of subjects: 20
Study 28513426 — intervention group
Group type: COMPARATOR
Intervention: Reference product (pregabalin 150-mg capsule)
Number of subjects: 20
Study 28513426 — intervention group
Group type: COMPARATOR
Intervention: Test and Reference products (pregabalin 150-mg capsule)
Number of subjects: 20
Study 24737669 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered intervention
Number of subjects: 782
Study 24737669 — intervention group
Group type: COMPARATOR
Intervention: Coach intervention
Number of subjects: 782
Study 24737669 — intervention group
Group type: COMPARATOR
Intervention: Automated voice response system
Number of subjects: 782
Study 24737669 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptomatology
Number of subjects: 782
Study 24737669 — intervention group
Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 782
Study 23453292 — intervention group
Group type: EXPERIMENTAL
Intervention: Scientific Hip Prosthesis (SHP)
Number of subjects: 75
Study 23453292 — intervention group
Group type: COMPARATOR
Intervention: Omnifit
Number of subjects: 75
Study 22094540 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel/gemcitabine (arm A: docetaxel 75 mg/m(2) on day 1, gemcitabine 1,000 mg/m(2) on days 1 and 8)
Number of subjects: 72
Study 22094540 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel/capecitabine (arm B: docetaxel 75 mg/m(2) on day 1, capecitabine 1,250 mg/m(2) twice daily on days 1-14)
Number of subjects: 72
Study 18443023 — intervention group
Group type: EXPERIMENTAL
Intervention: HBBS-treated groups
Number of subjects: 3711
Study 18443023 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 3711
Study 16826097 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-containing acrylic bone cement
Number of subjects: 90
Study 16826097 — intervention group
Group type: COMPARATOR
Intervention: Conventional acrylic bone cement
Number of subjects: 90
Study 12877614 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular brachytherapy (EVBT) with high-dose-rate (192)Ir irradiation (12 Gy for a reference vessel radius of 3 mm and a 2-mm reference depth)
Number of subjects: 100
Study 12877614 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty alone (control)
Number of subjects: 100
Study 11774060 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation (500 or 1000 mg of Vitamin C and 500 or 1000 IU of Vitamin E)
Number of subjects: 15
Study 11774060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9580355 — intervention group
Group type: EXPERIMENTAL
Intervention: Early retirement due to physical or accident purpose
Number of subjects: 78
Study 9580355 — intervention group
Group type: COMPARATOR
Intervention: Early retirement (general)
Number of subjects: 78
Study 8126620 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (5 g/kg/day)
Number of subjects: 29
Study 8126620 — intervention group
Group type: COMPARATOR
Intervention: Standard-protein diet (2.5 g/kg/day)
Number of subjects: 29
Study 2742633 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of the Brazelton neonatal behavioral assessment scale on 2- to 3-day-old infants.
Number of subjects: 44
Study 2742633 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 44
Study 239281 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of alcohol in smokers
Number of subjects: 0
Study 239281 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low dose of alcohol and tobacco in smokers
Number of subjects: 0
Study 239281 — intervention group
Group type: COMPARATOR
Intervention: Moderate dose of alcohol in nonsmokers
Number of subjects: 0
Study 239281 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking dose of nicotine with low levels of alcohol in smokers
Number of subjects: 0
Study 31545510 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol in cardiopulmonary bypass prime solution
Number of subjects: 0
Study 31545510 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31439215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe added to statin therapy
Number of subjects: 7195
Study 26887354 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT85 (submaximal interval training at 85% maximal aerobic power)
Number of subjects: 17
Study 26887354 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT115 (supramaximal interval training at 115% maximal aerobic power)
Number of subjects: 17
Study 26887354 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT85 (submaximal interval training)
Number of subjects: 17
Study 26887354 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT115 (supramaximal interval training)
Number of subjects: 17
Study 26261033 — intervention group
Group type: EXPERIMENTAL
Intervention: SPC5001 (5 mg kg(‐1))
Number of subjects: 24
Study 26261033 — intervention group
Group type: EXPERIMENTAL
Intervention: SPC5001
Number of subjects: 24
Study 26261033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23228252 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA) apical plugs
Number of subjects: 221
Study 21679324 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - 12 weeks of alpine ski training
Number of subjects: 42
Study 21679324 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - No intervention
Number of subjects: 42
Study 21679324 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IG and CG
Number of subjects: 42
Study 19339137 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in a Moderate Drinking protocol via an Internet-based program (www.moderatedrinking.com) and use of the online resources of Moderation Management (MM; www.moderation.org)
Number of subjects: 84
Study 19339137 — intervention group
Group type: COMPARATOR
Intervention: Use of the online resources of MM alone
Number of subjects: 84
Study 16897149 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 15262218 — intervention group
Group type: COMPARATOR
Intervention: Threatening words and images (TW)
Number of subjects: 60
Study 15262218 — intervention group
Group type: COMPARATOR
Intervention: Demanding cognitive load task (SR)
Number of subjects: 60
Study 15262218 — intervention group
Group type: COMPARATOR
Intervention: Exposure only (EO)
Number of subjects: 60
Study 15262218 — intervention group
Group type: COMPARATOR
Intervention: Neutral words and images (NW)
Number of subjects: 60
Study 11369725 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha‐tocopherol supplementation group
Number of subjects: 14011
Study 11369725 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 14011
Study 9403477 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (INR 3.0‐4.5)
Number of subjects: 1316
Study 9403477 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (30 mg daily)
Number of subjects: 1316
Study 29200069 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time 3D visualization during trial 1
Number of subjects: 69
Study 29200069 — intervention group
Group type: COMPARATOR
Intervention: Delayed visualization (playback of trial 2 before trial 3)
Number of subjects: 69
Study 29200069 — intervention group
Group type: COMPARATOR
Intervention: Real-time visualization and delayed visualization for the last trial
Number of subjects: 69
Study 29200069 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed reality simulator training
Number of subjects: 69
Study 27803391 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmoteplase (90 μg/kg)
Number of subjects: 252
Study 27803391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 23999733 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years basic parent training (IY)
Number of subjects: 52
Study 22396085 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (mean dose at delivery = 63.89 mg)
Number of subjects: 117
Study 22396085 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (mean dose at delivery = 14.05 mg)
Number of subjects: 117
Study 22396085 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 117
Study 22396085 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine consumption
Number of subjects: 117
Study 19249432 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,200 mg orally twice a day before and on the day of coronary catheterization (n = 106)
Number of subjects: 212
Study 19249432 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid 3 g and 2 g orally before, and 2 g twice after coronary catheterization with a 12-hour interval (n = 106)
Number of subjects: 212
Study 19249432 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) in diabetic subgroup
Number of subjects: 212
Study 19249432 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid in diabetic subgroup
Number of subjects: 212
Study 19249432 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) in patients with high dose of dye
Number of subjects: 212
Study 19249432 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid in patients with high dose of dye
Number of subjects: 212
Study 19249432 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 212
Study 19249432 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid
Number of subjects: 212
Study 19249432 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) in diabetic patients
Number of subjects: 212
Study 19249432 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid in diabetic patients
Number of subjects: 212
Study 16324889 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) operating system
Number of subjects: 0
Study 16324889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-post mixed-model ANCOVA
Number of subjects: 0
Study 16324889 — intervention group
Group type: EXPERIMENTAL
Intervention: Random coefficients models
Number of subjects: 0
Study 16324889 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage pre-post mixed-model ANCOVA
Number of subjects: 0
Study 15023582 — intervention group
Group type: EXPERIMENTAL
Intervention: Opiate addicts
Number of subjects: 39
Study 15023582 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 39
Study 11573660 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA) with remifentanil/propofol
Number of subjects: 40
Study 11573660 — intervention group
Group type: COMPARATOR
Intervention: Balanced anaesthesia (BAL) with etomidate/fentanyl/isoflurane
Number of subjects: 40
Study 11573660 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA)
Number of subjects: 40